Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 9/20 | 0.53 |
| ▸ | CCND1 | P24385 | 7/20 | 0.53 |
| ▸ | CCND2 | P30279 | 6/20 | 0.53 |
| ▸ | CCND3 | P30281 | 6/20 | 0.53 |
| ▸ | CCNE2 | O96020 | 3/20 | 0.53 |
| ▸ | CCNE1 | P24864 | 3/20 | 0.53 |
| ▸ | CDK2 | P24941 | 3/20 | 0.53 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.53 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.53 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.53 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.53 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.53 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | CSF1R | P07333 | 1/20 | 0.42 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.40 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3971327 | 0.88 | CDK4 (0.49) | CDK4CCND1CCND2CCND3CCNE2 | |
| SCHEMBL3973278 | 0.86 | CDK4 (0.46) | CDK4CCND1CCND2CCND3CCNE2 | |
| SCHEMBL3968472 | 0.84 | CDK4 (0.64) | CDK4CCND1CCND2CCND3CCNE2 | |
| SCHEMBL3965360 | 0.83 | CDK4 (0.52) | CDK4CCND1CCND2CCND3CCNE2 | |
| SCHEMBL3971442 | 0.83 | CDK4 (0.44) | CDK4CCND1CCND2CCND3CCNE2 | |
| SCHEMBL3972389 | 0.82 | CDK4 (0.68) | CDK4CCND1CCND2CCND3CCNE2 | |
| SCHEMBL5266174 | 0.81 | CDK4 (0.80) | CDK4CCND1CCND2CCND3CCNE2 | |
| SCHEMBL3972187 | 0.81 | CDK4 (0.52) | CDK4CCND1CCND2CCND3CCNE2 | |
| SCHEMBL6639837 | 0.79 | CDK4 (0.45) | CDK4CCND1CCND2CCND3CCNE2 | |
| SCHEMBL4714586 | 0.77 | CDK4 (0.78) | CDK4CCND1CCND2CCND3CCNE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501425-B1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyprimidines as inhibitors of cellular proliferation | WARNER LAMBERT COMPANY (US) | 2009-03-10 | — | — | US | claimed |
| EP-1080092-B1 | BICYCLIC PYRIMIDINES AND BICYCLIC 3,4-DIHYDROPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2008-07-23 | — | — | EP | claimed |
| EP-1801112-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | Warner-Lambert Company LLC (US) | 2007-06-27 | — | — | EP | claimed |
| US-7501425-B1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyprimidines as inhibitors of cellular proliferation | WARNER LAMBERT COMPANY (US) | 2009-03-10 | — | — | US | disclosed |
| EP-1080092-B1 | BICYCLIC PYRIMIDINES AND BICYCLIC 3,4-DIHYDROPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER LAMBERT CO (US) | 2008-07-23 | — | — | EP | disclosed |
| US-20040044012-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | DOBRUSIN ELLEN MYRA (US) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044012-A1 | Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation | CCNI, CCNH, CCNA1 | CDK4 4/4885CCND1 13/4885CCND2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.